Knoerl, Robert
Berry, Donna
Meyerhardt, Jeffrey A.
Reyes, Kaitlen
Salehi, Elahe
Thornton, Katherine
Gewandter, Jennifer S.
Funding for this research was provided by:
Rita and Alex Hillman Foundation
National Institute of Neurological Disorders and Stroke (K24NS126861)
Article History
Received: 18 April 2022
Accepted: 31 October 2022
First Online: 10 November 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Dana-Farber/Harvard Cancer Center Office for Human Research Studies (Protocol: 19–535; 11/22/2019).
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: RK has received personal fees (consulting) from Strategy Inc., Spark Healthcare, Fors Marsh Group, Osmol Therapeutics, Inc., and the Comprehensive and Integrative Medicine Institute and serves on the scientific advisory board of Wellium. JM has served as an advisor/consultant to Merck Pharmaceutical and COTA Healthcare. JG has received grant funding from the National Institutes of Health, compensation for grant reviews from the US Department of Defense, and consulting income from Algo Therapeutix, Asahi Kasei Pharma, Eikonizo Therapeutics, GW Pharma, Magnolia Neurosciences, Orthogonal Neurosciences, Science Branding Communications, SK Life Science, and Saluda Medical.
Free to read: This content has been made available to all.